35.71MMarket Cap-998P/E (TTM)
3.2614High2.9001Low11.65KVolume3.0500Open3.0500Pre Close35.12KTurnover0.18%Turnover RatioLossP/E (Static)12.14MShares4.400052wk High-9.64P/B19.30MFloat Cap1.077552wk Low--Dividend TTM6.57MShs Float5000.0000Historical High--Div YieldTTM11.85%Amplitude1.0775Historical Low3.0130Avg Price1Lot Size
Akari Therapeutics Stock Forum
Akari Therapeutics Receives Positive and Constructive Pre-Ind Feedback From US FDA for Pas-Nomacopan in Treatment of Geographic Atrophy
Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity
•Prioritization of Peak’s ADC cancer therapeutic platform technology and Akari’s PAS-nomacopan for Geographic Atrophy, a disabling ophthalmic disease•Akari Therapeutics announces leadership changes in separate Akari press release
BOSTON and PLEASANTON, May 1, 2024 (GLOBE NEWSWIRE) - Akari Therapeutics, Plc ...
8 MINUTES AGO, 8:00 AM EDT
VIA GLOBENEWSWIRE
No comment yet